Stay updated on Pembrolizumab in Medullary Thyroid Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Medullary Thyroid Cancer Clinical Trial page.

Latest updates to the Pembrolizumab in Medullary Thyroid Cancer Clinical Trial page
- ChecktodayChange DetectedThe web page has undergone significant updates, including the addition of specific medical terms related to medullary thyroid gland carcinoma and the introduction of a new facility name and location. Notably, the version has been updated to v3.0.0.SummaryDifference2%
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.0%
- Check22 days agoChange DetectedThe web page has been updated from version v2.16.10 to v2.16.11.SummaryDifference0.0%
- Check29 days agoChange DetectedThe web page has been updated to version 2.16.10, and a previous service alert regarding planned maintenance has been removed.SummaryDifference0.6%
- Check36 days agoChange DetectedThe web page has been updated to reflect a new version, changing from Revision v2.16.6 to v2.16.8, and it now includes information about HHS Vulnerability Disclosure.SummaryDifference0.1%
- Check43 days agoChange DetectedThe web page has been updated from version 2.16.5 to version 2.16.6.SummaryDifference0.0%
Stay in the know with updates to Pembrolizumab in Medullary Thyroid Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Medullary Thyroid Cancer Clinical Trial page.